Prenetics Global (PRE) Projected to Post Earnings on Wednesday

Prenetics Global (NASDAQ:PRE) is projected to issue its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $36.15 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 10:00 AM ET.

Prenetics Global Trading Up 4.8%

Shares of PRE opened at $21.97 on Monday. The company has a market cap of $369.76 million, a price-to-earnings ratio of -10.82 and a beta of 0.35. The business’s fifty day simple moving average is $17.26 and its two-hundred day simple moving average is $13.64. Prenetics Global has a 12 month low of $3.09 and a 12 month high of $22.86.

Analysts Set New Price Targets

Several research firms recently commented on PRE. Cantor Fitzgerald lifted their price objective on Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Roth Mkm initiated coverage on shares of Prenetics Global in a research note on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $34.00.

Institutional Investors Weigh In On Prenetics Global

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP purchased a new position in Prenetics Global during the fourth quarter valued at $788,000. Jane Street Group LLC bought a new position in shares of Prenetics Global in the fourth quarter worth about $1,302,000. Goldman Sachs Group Inc. purchased a new position in shares of Prenetics Global during the 4th quarter valued at about $665,000. UBS Group AG lifted its position in shares of Prenetics Global by 581.9% during the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after buying an additional 39,733 shares in the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in shares of Prenetics Global during the 4th quarter valued at approximately $296,000. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.